Anupam Rasayan to Launch Open Offer for Bliss GVS Pharma Limited
Anupam Rasayan India Limited has announced a mandatory Open Offer for the public shareholders of Bliss GVS Pharma Limited. The Open Offer is being conducted in compliance with regulations governing substantial acquisitions of shares.The mandatory Open Offer, managed by SBI Capital Markets Limited, is for the acquisition of up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited. This quantity represents 26.00% of the company’s Expanded Voting Share Capital.
The offer has been priced at ₹ 299.00 per Offer Share. Should the Acquirer receive full acceptance of the Open Offer, the total consideration payable would be up to ₹ 8,29,03,27,552.00.
Underlying Acquisition Details
The Open Offer is triggered by an Underlying Transaction detailed in a Share Purchase Agreement (SPA) executed on May 23, 2026, between Anupam Rasayan India Limited and certain sellers of Bliss GVS Pharma Limited (the Target Company).Under the SPA, Anupam Rasayan India Limited agreed to acquire 4,58,03,024 equity shares from the sellers. These shares represent 43.30% of the Target Company’s equity share capital as of the date of the agreement. The sale and purchase of these shares are proposed to be executed at a price not exceeding ₹ 299.00 per equity share.
The total consideration for the shares acquired through the SPA is up to ₹ 13,69,51,04,176.00.
Company Financial Overviews
The filings provide key financial information for both the Acquirer and the Target Company, based on audited consolidated financial statements for the period ended March 31, 2026.Bliss GVS Pharma Limited (Target Company) Financials
| Parameter | FY ended and as at 31 March 2026 | FY ended and as at 31 March 2025 | FY ended and as at 31 March 2024 |
|---|---|---|---|
| Total Revenue | ₹ 1,000.64 crore | ₹ 846.22 crore | ₹ 798.98 crore |
| Net Income | ₹ 134.73 crore | ₹ 90.26 crore | ₹ 81.58 crore |
| Basic EPS (₹) | 12.23 | 8.02 | 7.23 |
| Net worth / Shareholders' Funds (₹ crore) | 1,192.90 | 1,050.38 | 967.19 |
Anupam Rasayan India Limited (Acquirer) Financials
| Parameter | FY ended and as at 31 March 2026 | FY ended and as at 31 March 2025 | FY ended and as at 31 March 2024 |
|---|---|---|---|
| Total Revenue | ₹ 2,383.63 crore | ₹ 1,448.45 crore | ₹ 1,505.32 crore |
| Net Income | ₹ 222.20 crore | ₹ 159.97 crore | ₹ 167.43 crore |
| Basic EPS (₹) | 15.09 | 8.50 | 11.89 |
| Net worth / Shareholders' Funds (₹ crore) | 4,629.96 | 3,081.66 | 2,930.65 |
The Equity Shares of Bliss GVS Pharma Limited are listed on the BSE (Scrip Code: 506197) and the NSE (Symbol: BLISSGVS). The Target Company is primarily engaged in the manufacturing of pharmaceutical products.
BLISSGVS Stock Price Movement
Bliss GVS Pharma Limited shares today slipped by 5.38% to settle at ₹402.45, marking a weaker close for the stock. The equity traded on robust volume, processing 3.02 million shares throughout the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.